Edwards Lifesciences Corporation (EW)

In October 2025, Edwards Lifesciences reported Q3 earnings per share of $0.67, surpassing estimates, with revenue of $1.55 billion. Several analysts upgraded the stock and adjusted price targets upwards in November and December 2025 and January 2026. Several officers sold shares in late 2025 and early January 2026. In January 2026, a U.S. District Court blocked Edwards Lifesciences' acquisition of JenaValve Technology, leading to a revision of the company's full-year 2026 adjusted EPS guidance and a decrease in share price. As of January 12, 2026, EW stock was down 0.44% over the past 30 days but up 16.77% over the past 12 months.

Edwards Lifesciences' products and services do not have significant demand seasonality explicitly stated. The company compiles a rolling 24-month global demand forecast and analyzes changing demand trends. Demand is influenced by procedure volumes, innovation cycles, and hospital spending trends in cardiovascular markets. Growth drivers include greater awareness, patient access, advances in new technologies, indication expansion, and increased global adoption of its TAVR and TMTT platforms.

Edwards Lifesciences Corporation is a medical technology company focused on patient-centered innovations for cardiovascular diseases. Their products and technologies are in transcatheter aortic valve replacement (TAVR), transcatheter mitral and tricuspid therapies (TMTT), surgical structural heart, and critical care, though the Critical Care business unit was sold to BD in 2024. The company's products are used in therapies such as TAVR, blood conservation, infection control, enhanced surgical recovery, and the management of clotting, hypotension, and sepsis.

Edwards Lifesciences is headquartered in Irvine, California, and markets its products globally through direct sales and distributors in North America, Europe, Japan, and Asia-Pacific. It has manufacturing facilities in Draper, Utah; Costa Rica; the Dominican Republic; Puerto Rico; Singapore; and Limerick, Ireland.

Edwards Lifesciences has a strong brand reputation due to its focus on structural heart innovation and patient-centered culture. The company is recognized for its innovations and commitment to transforming care for structural heart patients. Events affecting its reputation include the sale of the Critical Care business, clinical trial successes, FDA approvals, and the blocked acquisition of JenaValve Technology.

Edwards Lifesciences Corporation is primarily controlled by institutional shareholders, who own approximately 84% of the company. The top 25 shareholders collectively own 50% of the company. Major institutional owners include The Vanguard Group, Inc., BlackRock, Inc., and State Street Corp. Individual insider ownership is less than 1% of the company, with Michael A. Mussallem being the largest individual shareholder.